학술논문

BENEFIT–RISK PROFILES OF FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL (FF/UMEC/VI) VS UMEC/VI IN PATIENTS WITH COPD: A MARKOV MODEL